Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00210
|
|||||
| Drug Name |
Alprostadil
|
|||||
| Synonyms |
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Alista; Alprostadil (JP15/USP/INN); Alprostadil Prostoglandin E1; Alprostadilum; Alprox-TD; BML1-F06; Befar; Befar (TN); Caverject; Caverject (TN); Edex; Edex (TN); FemLife; Femprox; HEI-507; L-Prostaglandin E1; MR 256; MR-256; Muse; Muse (TN); PGE1; PGE1 Oligomer; Prink; Prink (TN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; Prostaglandin E1; Prostavasin; Prostin VR; Prostin VR Pediatric; Prostin VR pediatric (TN); RayVa; Sugiran; Topiglan; U-10136; Viridal; Vitaros
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Erectile dysfunction [ICD11: HA01] | Approved | [1] | |||
| Therapeutic Class |
Vasodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H34O5
|
|||||
| Canonical SMILES |
CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O
|
|||||
| InChI |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
|
|||||
| InChIKey |
GMVPRGQOIOIIMI-DWKJAMRDSA-N
|
|||||
| CAS Number |
CAS 745-65-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 354.5 | Topological Polar Surface Area | 94.8 | ||
| Heavy Atom Count | 25 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103171219
, 103914567
, 12013405
, 14901054
, 14901056
, 24887977
, 24890439
, 24898661
, 24898855
, 24898994
, 26719695
, 26752225
, 26752226
, 3139926
, 39289772
, 4266050
, 46386879
, 46386882
, 46387002
, 47216549
, 47515087
, 47515088
, 47810514
, 47959471
, 48110217
, 48184750
, 48415538
, 49681576
, 49699251
, 50104916
, 50104917
, 53790811
, 57357853
, 57654538
, 7312
, 77812073
, 7847248
, 7978676
, 8143220
, 85789478
, 8616376
, 91702047
, 92126041
, 92308647
, 92309224
, 92309904
, 92712130
, 93166905
, 99300818
, 99302336
|
|||||
| ChEBI ID |
ChEBI:15544
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [2] | |
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [3] | ||
| OATP2A1 | Transporter Info | Organic anion transporting polypeptide 2A1 | Substrate | [4] | ||
| OATP3A1 | Transporter Info | Organic anion transporting polypeptide 3A1 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | MRP4 | Transporter Info | Km = 2.1 microM | Spodoptera frugiperda (Sf9) cells-MRP4 | [2] | |
| OATP3A1 | Transporter Info | Km = 0.0485 microM | Oocytes-OATP3A1 | [5] | ||
| References | ||||||
| 1 | Alprostadil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. | |||||
| 3 | Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7. | |||||
| 4 | Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. | |||||
| 5 | Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.